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Abstract
Aims/hypothesis Serum extracellular nicotinamide
phosphoribosyltransferase (eNAMPT) concentrations are
elevated in type 2 diabetes. However, the relationship between
abnormally elevated serum eNAMPT and type 2 diabetes
pathophysiology is unclear. eNAMPT circulates in function-
ally and structurally distinct monomeric and dimeric forms.
Dimeric eNAMPT promotes NAD biosynthesis. The role of
eNAMPT-monomer is unclear but it may have NAD-
independent proinflammatory effects. However, studies of
eNAMPT in type 2 diabetes have not distinguished between
monomeric and dimeric forms. Since type 2 diabetes is
characterised by chronic inflammation, we hypothesised a
selective NAD-independent role for eNAMPT-monomer in
type 2 diabetes.
Methods Twomouse models were used to examine the role of
eNAMPT-monomer in type 2 diabetes; (1) a mouse model of
diabetes fed a high-fat diet (HFD) for 10 weeks received i.p.
injections with an anti-monomeric-eNAMPT antibody; and
(2) lean non-diabetic mice received i.p. injections with recom-
binant monomeric eNAMPT daily for 14 days.
Results Serum monomeric eNAMPT levels were elevated in
HFD-fed mouse models of diabetes, whilst eNAMPT-dimer
levels were unchanged. eNAMPT-monomer neutralisation in
HFD-fed mice resulted in lower blood glucose levels, amelio-
ration of impaired glucose tolerance (IGT) and whole-body
insulin resistance, improved pancreatic islet function, and
reduced inflammation. These effects were maintained for at
least 3 weeks post-treatment. eNAMPT-monomer administra-
tion induced a diabetic phenotype in mice, characterised by
elevated blood glucose, IGT, impaired pancreatic insulin
secretion and the presence of systemic and tissue inflamma-
tion, without changes in NAD levels.
Conclusions/interpretation We demonstrate that elevation of
monomeric-eNAMPT plays an important role in the patho-
genesis of diet-induced diabetes via proinflammatory mecha-
nisms. These data provide proof-of-concept evidence that the
eNAMPT-monomer represents a potential therapeutic target
for type 2 diabetes.
Keywords Beta cell . Extracellular nicotinamide
phosphoribosyltransferase . eNAMPT . Inflammation . Islet .
Type 2 diabetes
Abbreviations
AT Adipose tissue
CCL2 Chemokine (C-C motif) ligand 2
CON Control diet
CONAb Control diet-fed mice, administered eNAMPT-
antibody
CONIgG Control diet-fed mice, administered IgG
HFD High-fat diet
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HFDAb High-fat diet-fed mice, administered eNAMPT-
antibody
HFDIgG High-fat diet-fed mice, administered IgG
IGT Impaired glucose tolerance
iNAMPT Intracellular nicotinamide
phosphoribosyltransferase
eNAMPT Extracellular nicotinamide
phosphoribosyltransferase
GSIS Glucose-stimulated insulin secretion
HFD High-fat diet
iNAMPT Intracellular nicotinamide
phosphoribosyltransferase
MCP1 Monocyte chemoattractant protein
NAFLD Non-alcoholic fatty liver disease
NAMPT Nicotinamide phosphoribosyltransferase
NMN Nicotinamide mononucleotide
PBEF Pre-B cell colony-enhancing factor
qRT-PCR Quantitative RT-PCR
SVF Stromal vascular fraction
Introduction
Type 2 diabetes is characterised by the presence of peripheral
insulin resistance and pancreatic beta cell dysfunction [1].
Determining the precise pathophysiological mechanisms re-
sponsible for these processes is essential for the development
of novel therapeutics.
Serum concentrations of extracellular nicotinamide
phosphoribosyltransferase (eNAMPT; also referred to as
visfatin/pre-B cell colony-enhancing factor [PBEF]) are com-
monly elevated in type 2 diabetes patients [2], whilst raised
eNAMPT levels strongly correlate with declining beta cell
function [3]. Therefore, a pathophysiological role is implied
for eNAMPT in type 2 diabetes. However, other studies have
reported both insulin sensitising and beta cell protective
effects of eNAMPT [4–7]. Therefore, the precise relationship
between elevated eNAMPT and type 2 diabetes remains
unresolved.
Nicotinamide phosphoribosyltransferase exists in intracel-
lular (iNAMPT) and extracellular (eNAMPT) forms.
iNAMPT is widely expressed and is a well-characterised
NAD biosynthetic enzyme [8]. In contrast, the function of
eNAMPT is unclear, although putative proinflammatory [9,
10], insulin-mimetic [11] and NAD biosynthetic functions
[5, 12, 13] have been described. These disparate putative func-
tions are controversial and have been challenged [11, 14], but
may be explained by the presence of structurally and function-
ally distinct monomeric (50 kDa) and dimeric (100 kDa)
forms of eNAMPT. Dimerisation is reportedly essential for
the biosynthetic functions of NAMPT [5, 15]. The
eNAMPT-monomer has potential NAD-independent proin-
flammatory effects. However, the precise structure–function
relationships have not yet been fully investigated, particularly
within the context of type 2 diabetes pathophysiology.
Given the crucial role of chronic inflammation in type 2
diabetes pathophysiology, we hypothesised that eNAMPT-
monomer levels will be selectively elevated in type 2 diabetes
and by potentially acting in a proinflammatory manner, may
play a key role in type 2 diabetes pathophysiology.
Methods
Animal studies For immunoneutralisation experiments,
8-week-old male C57Bl/6 mice (Charles River, Margate,
UK) were fed a high-fat diet (HFD; 60% wt/wt fat; 58Y1;
Test Diets, St. Louis, MO, USA) or a control diet (CON) for
10 or 13 weeks, and then injected i.p. with a rabbit polyclonal
mouse anti-eNAMPT antibody (2.5 μg/ml; LS-C48964;
LifespanBio, WA, USA) or a non-immune IgG equivalent
(four separate doses during weeks 9–10). Antibodies were
validated via immunoprecipitation and immunoblotting.
Mice were then killed either directly post-treatment
(at 10 weeks) or 3 weeks later (at 13 weeks; n=24/group)
For experimental elevation of eNAMPT and nicotinamide
mononucleotide (NMN), 8-week old male C57Bl/6 mice were
i.p. injected daily with either recombinant eNAMPT (5 ng/ml;
Adipogen, Seoul, South Korea), NMN (500 mg/kg body
weight; Sigma, Poole, UK) or the equivalent volume of
NaCl 154 mmol/l (Sigma) for 14 days (n=8/group).
Mice were maintained on a 12 h light/12 h dark cycle.
Animal experiments were conducted in accordance with UK
Home Office Animals (Scientific Procedures) Act 1986, with
local ethical committee approval. Experimenters were not
blinded to group assignment or outcome assessment.
Specific randomisation of animals into groups was not carried
out. No data, samples or animals were excluded from the
study.
IPGTTand in vivo insulin secretionMice were fasted over-
night then injected i.p. with 2 g/kg body weight 25% wt/vol.
dextrose (Sigma). Glucose was measured in tail vein blood
samples (Accuchek, Roche Diagnostics, Burgess Hill, UK)
between 0 and 120 min. Additional blood was collected dur-
ing the IPGTT to estimate the insulin secretory response to
glucose.
Model assessments of insulin resistanceWhole-body insulin
resistance and sensitivity were assessed using three equations:
(1) insulin resistance (IR) = fasting glucose (mmol/l) × fasting
insulin (pmol/l); (2) HOMA-IR (log HOMA-IR = log10
[fasting insulin (pmol/l) × fasting glucose (mmol/l) ÷ 22.5]);
and (3) QUICKI = (1/log10 [fasting insulin (pmol/l)] + log10
[fasting glucose(mmol/l)]).
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Blood chemistry Blood was obtained by cardiac puncture.
Serum and liver triacylglycerol levels were determined using
a colourimetric assay kit (Cayman Chemical, Ann Arbor, MI,
USA). Serum NEFA levels were measured using a fluoromet-
ric assay (Abcam, Cambridge, UK). ELISA kits were used to
measure serum insulin (Mercodia, Uppsala, Sweden),
eNAMPT (Caltag, Buckingham, UK), and TNF-α, IL-1β
and MCP1 (eBioscience, Hatfield, UK).
Serum NMN and tissue NAD levels Serum NMN was
detected fluorometrically by HPLC, using a modified version
of a previously described methodology (see electronic supple-
mentary material [ESM] Methods) [16]. Tissue NAD levels
were determined using a NAD/NADH quantification kit
(Sigma).
Immunoblotting Immunoblotting was conducted as previ-
ously described [17] using primary antibodies against
NAMPT (Sigma or Bethyl Laboratories, Montgomery, TX,
USA), p-Akt(Ser473) and total Akt (both Cell Signaling
Technologies, Danvers, MA, USA). All primary antibodies
were rabbit anti-mouse polyclonal antibodies and were used
at a 1:1000 dilution. Validation was conducted via immuno-
blot. NAMPT immunoprecipitation was carried out using a
Catch and Release Reversible Immunoprecipitation System
(Millipore, Watford, UK).
Quantitative RT-PCR Gene expression was determined by
TaqMan or SYBR green quantitative RT-PCR (qRT-PCR)
[17], using ΔΔCt methodology, and normalised against 18S
ribosomal RNA levels (Applied Biosystems, Warrington,
UK). Changes in gene expression are normalised to control.
For details of primers (Eurogentec, Southampton, UK), see
ESM Table 1
Mouse islet isolation and insulin secretion Mouse
pancreases were digested in 2 ml Hanks Buffered Salt
Solution (HBSS) containing 1 mg/ml collagenase P and
0.15 mg/ml DNAse I (both Roche Diagnostics). Islets were
hand-picked and transferred into RPMI 1640 medium for
RNA extraction or insulin secretion assays. For islet insulin
secretion assays, batches of eight size-matched islets were pre-
incubated for 1 h at 37°C in HBSS containing 3 mmol/l
glucose, 10 mmol/l HEPES (pH 7.4) and 0.2% BSA (wt/
vol.). For glucose-stimulated insulin secretion (GSIS) analy-
sis, islets were incubated for 1 h at 37°C in HBSS containing
10 mmol/l HEPES (pH 7.4) and 0.2% BSA, supplemented
with 3 mmol/l or 17 mmol/l glucose. After 1 h, the medium
was collected for determination of insulin levels by ELISA
(see ESM Methods ‘islet isolation’ and ‘insulin secretion
ex vivo’ for further details).
Immunofluorescence analysis of mouse pancreatic sections
Immunostaining was conducted as previously described [7].
Briefly, the whole pancreas was fixed in buffered formalin,
embedded in paraffin, cut into sections and stained with guin-
ea pig anti-insulin (1:100 dilution; Abcam) and/or rabbit anti-
p-P38 (1:1600 dilution; Cell Signaling Technologies) antibod-
ies. Sections were then mounted on glass cover slips and
analysed using a Leica DM5000 epifluorescence microscope
with Leica Application Suite software (Leica, Milton Keynes,
UK) (see ESM Methods).
MIN6 cell culture and treatment MIN6 beta cells were
incubated with 2–10 ng/ml eNAMPT (Adipogen) with or
without anti-eNAMPT antibody (2.5 μg/ml; LS-C48964)
and analysed for changes in insulin secretion or NAD levels
(see ESM Methods). MIN6 cells were free from mycoplasma
contamination
Isolation of white adipocytes and the stromal vascular
fraction White adipocytes and the stromal vascular fraction
(SVF) were isolated from epididymal white adipose tissue
(AT) according to previously described methodology [18].
Isolated adipocyte and SVF preparations were incubated for
3.5 h at 37°C in DMEM containing 25 mmol/l glucose. The
medium was then collected and analysed for eNAMPT con-
tent by ELISA (Caltag).
Statistical analysisResults are expressed as the mean±SEM.
Statistical differences were calculated by one-way ANOVA
and the Tukey’s test where appropriate (GraphPad Software;
la Jolla, CA, USA).
Results
High-fat feeding selectively induces the production and
secretion of eNAMPT-monomerWe first demonstrated that
serum eNAMPT levels were elevated in diabetic HFD-fed
mice (Fig. 1a).
Following this, we examined whether increased total
eNAMPT was associated with specific changes in eNAMPT-
monomer or eNAMPT–dimer levels using non-reducing
SDS-PAGE and immunoblotting. Indicative of a selective
diabetogenic function, eNAMPT-monomer protein levels
were markedly elevated in serum (82.0±1.9%; Fig. 1b, c) of
HFD-fed mice compared with CON-fed mice. In contrast,
serum levels of the eNAMPT-dimer and its reaction product,
NMN, were non-significantly reduced or unchanged between
HFD- vs CON-fed mice (Fig. 1b–d). Similar changes were
observed in white AT, a major source of circulating
eNAMPT. White AT from HFD-fed mice had increased
Nampt mRNA levels (Fig. 1e), with parallel increases in the
NAMPT-monomer (64.0±5.9%), but no observed changes in
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NAMPT-dimer or NAD (Fig. 1f–h). Therefore, alterations in
the levels and structure of NAMPT in white AT provide a
potential explanation for increased serum eNAMPT-
monomer and eNAMPT-dimer levels in HFD-fed mice.
To further examine the source of eNAMPT, we isolated
white adipocytes and SVF from epididymal white ATand mea-
sured eNAMPT secretion. In white adipocytes from HFD-fed
mice eNAMPT secretion was markedly decreased, whilst
eNAMPT secretion was increased in SVF isolated from HFD-
fed mice (Fig. 1i, j). Collectively, this suggests that white adi-
pocytes and SVF are likely to be the primary source of
eNAMPT-dimer and eNAMPT-monomer, respectively. The
cellular source of eNAMPT-monomer within the SVF requires
further study. However, previous studies have reported
eNAMPT secretion from undifferentiated pre-adipocytes and
immune cells, including macrophages, neutrophils and B cells.
Together these data demonstrate that serum levels of
eNAMPT-monomer are selectively elevated in diabetic
HFD-fed mice. This implies a specific pathophysiological role
for eNAMPT-monomer in experimental diabetes.
Anti-Anti-eNAMPT antibody improves glycaemic control
and insulin resistance in HFD-fed mice To determine the
importance of raised serum eNAMPT-monomer levels in ex-
perimental diabetes, HFD- and CON-fed mice were injected
i.p. with an anti-eNAMPT antibody (eNAMPT-Ab) or non-
immune IgG equivalent (2 doses/week in weeks 9–10).
Immunoneutralisation enables the selective inhibition of
circulating eNAMPT (without inhibiting iNAMPT).
Immunoprecipitation of NAMPTwith this antibody followed
by immunoblotting led to detection of a 50 kDa protein band
but not a 100 kDa protein band (ESM Fig. 1a, b), indicating
antibody specificity for the eNAMPT-monomer. Moreover,
eNAMPT-Ab blocked NAD-independent eNAMPT-mediated
decreases in GSIS inMIN6 cells but did not have any effect on
levels of NMN (the eNAMPT-dimer reaction product) in
HFD- or CON-fed mice (ESM Fig. 1c, d). This result suggests
that the eNAMPT-Ab selectively targets the eNAMPT-mono-
mer. Serum levels of total eNAMPT were non-significantly
reduced following eNAMPT-Ab treatment (ESM Fig. 1e).
In support of a diabetogenic role for the eNAMPT-mono-
mer, eNAMPT-Ab administration reduced blood glucose and
insulin levels (Fig. 2a–c) and corrected impaired glucose toler-
ance (IGT) in HFD-fed mice (Fig. 2d–f). As determined by
assessment of the insulin × glucose product, HOMA-IR and
QUICKI, eNAMPT-Ab also ameliorated whole-body insulin
resistance (Fig. 2g–i). Improved glucose tolerance and insulin
sensitivity were associated with reduced fasting serum triacyl-
glycerol and fed serum NEFA levels, although the latter did not
reach statistical significance. Fed serum triacylglycerol levels
were unchanged across all groups (ESM Fig. 2a–c). Body
weight and food intake were also unchanged (ESM Fig. 2d, e).
Together, these data demonstrate that neutralising the
eNAMPT-monomer leads to a marked improvement in the
diabetic phenotype of HFD-fed mice.
eNAMPT-Ab improves pancreatic islet function and
increases islet size in HFD-fed mice Type 2 diabetes is
characterised by progressive pancreatic beta cell failure [1].
Therefore, we assessed whether eNAMPT-Ab mediated
improvements in glycaemic control via improvements in beta
cell/islet health.
Fig. 1 eNAMPT-monomer
levels are selectively elevated in
HFD-fed mice. (a) Total serum
eNAMPT, (b, c) serum eNAMPT
monomeric and dimeric protein
and (d) serum NMN levels in
CON- or HFD-fed mice (fed for
10 weeks); in (c) white bars,
CON-fed; black bars, HFD-fed.
(e) Nampt mRNA expression
(normalised to control levels
[levels in CON-fed mice]),
(f, g) NAMPT-monomer and
NAMPT-dimer protein levels
(normalised to control [CON-
fed]) and (h) total NAD levels in
white AT (in (c) and (g), white
bars, CON-fed; black bars, HFD-
fed). eNAMPT secretion from
(i) SVF and (j) white adipocytes.
Western blots are representative
of three separate blots. *p< 0.05,
**p< 0.01
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Beta cell/islet function was impaired in HFD-fed
mice, as evidenced by the lack of an islet compensatory
response to insulin resistance in static ex vivo GSIS
studies (Fig. 3a), and in vivo measurements of the first
(0–15 min) and second phase (15–60 min) insulin
secretory responses to glucose (Fig. 3b, c). Crucially,
eNAMPT immunoneutralisation restored islet compensa-
tion, as demonstrated by a marked increase in ex vivo
GSIS and in vivo first phase insulin secretion in HFD-
fed mice, administered eNAMPT-antibody (HFDAb).
Fig. 2 eNAMPT-monomer
immunoneutralisation reverses
the diabetic phenotype in HFD-
fed mice. (a) Fasting serum
glucose, (b) fed serum glucose,
(c) fed serum insulin,
(d–f) glucose response to IPGTT
(black, CONIgG; green, CON-fed
mice, administered eNAMPT-
antibody [CONAb]; red, HFDIgG;
blue, HFDAb) in CON- and HFD-
fed mice (fed for 10 weeks)
treated with eNAMPT-Ab or non-
immune IgG. (g) Insulin ×
glucose product, (h) HOMA-IR
and (i) QUICKI. *p < 0.05,
**p< 0.01, ***p< 0.001 for all
subparts except (d) where
†p < 0.05, ††p< 0.01, †††p < 0.001
for CONIgG vs HFDIgG and
‡p < 0.05 for HFDIgG vs HFDAb
Fig. 3 eNAMPT
immunoneutralisation reverses
beta cell dysfunction in HFD-fed
mice. (a) Ex vivo GSIS and (b, c)
AUC insulin response to IPGTT
in CON- and HFD-fed mice (fed
for 10 weeks) i.p. injected with
eNAMPT-Ab or non-immune
IgG. (d) Insulin
immunofluorescence staining of
whole pancreatic sections
(magnification ×20), (e) relative
islet size (AU, arbitrary unit) and
(f) gene expression of pro-
apoptotic genes in isolated islets
(normalised to control [CONIgG]).
(a, f) white, CONIgG; light grey,
CONAb; black, HFDIgG; dark
grey, HFDAb. *p < 0.05,
** p< 0.01 for all subparts except
(f) where †††p< 0.001 for CONIgG
vs HFDIgG, ‡‡‡p < 0.001 for
HFDIgG vs HFDAb and §§p< 0.01
for CONAb vs HFDIgG
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We next assessed the effects of the eNAMPT-Ab on islet
size. Islet size was reduced by 46% (p<0.01) in HFD-fed mice,
administered IgG (HFDIgG) compared with CON-fed mice, ad-
ministered IgG (CONIgG); this effect was completely reversed
by eNAMPT-Ab treatment (Fig. 3d, e). Several studies have
observed an increased islet size in HFD-fed mice. However, in
this study the reduced islet size observed is likely to reflect
progression from insulin resistance to an overt diabetic pheno-
type in our model. Beta cell apoptosis and necrosis are com-
monly considered to be mechanisms responsible for reduced
beta cell/islet mass in type 2 diabetes. Consistent with this, islet
mRNA levels of pro-apoptotic and necrotic markers were sig-
nificantly elevated in HFD-fed mice (Fig. 3f). Strikingly,
mRNA levels of these genes were lowered to basal levels
following eNAMPT-Ab administration, demonstrating that
eNAMPT immunoneutralisation improves beta cell function/
mass in part by protecting against beta cell apoptosis and necro-
sis. Together, these data demonstrate that eNAMPT immuno-
neutralisation improves glycaemic control in HFD-fed mice in
part through reversing beta cell dysfunction and restoring islet
compensation.
eNAMPT-Ab improves hepatic insulin sensitivity and re-
duces hepatic fat contentObesity-induced non-alcoholic fat-
ty liver disease (NAFLD), characterised by excess hepatic
lipid accumulation and inflammation, is an established risk fac-
tor for the development of hepatic insulin resistance and type 2
diabetes [19]. Elevated serum eNAMPT levels in NAFLD are
associated with worsening disease severity [20]. Consistent
with a potential role for eNAMPT-monomer in the develop-
ment of fatty liver, the eNAMPT-Ab reversed HFD-mediated
increases in hepatic triacylglycerol content (ESM Fig. 3a) and
changes in Srebf1 and Fasn lipogenic gene expression (ESM
Fig. 3b). Hepatic insulin resistance is strongly associated with
increased liver lipid content. Moreover, eNAMPT-Ab reversed
HFD-mediated decreases in hepatic protein levels of -p-Akt
(Ser473), a marker of insulin signalling (ESM Fig. 3c), and
corrected abnormally elevated mRNA levels of Pck1 (ESM
Fig. 3b), a key gluconeogenic gene. Together, these data sug-
gest that eNAMPT immunoneutralisation lowers hepatic lipid
content andmay improve hepatic insulin sensitivity in HFD-fed
mice.
eNAMPT-Ab ameliorates tissue and systemic inflamma-
tion in HFD-fed mice Chronic inflammation causes beta cell
failure in type 2 diabetes [21]. Proinflammatory functions of
eNAMPT have been reported, although studies have not dis-
tinguished between monomeric and dimeric forms [10], nor
have they examined a specific proinflammatory role for
eNAMPT in type 2 diabetes. The eNAMPT-Ab lowered
HFD-mediated increases in serum monocyte chemoattractant
protein (MCP-1; also known as chemokine (C-Cmotif) ligand
2[CCL2]) levels (Fig. 4a), although serum TNF-α and IL-1β
levels were similar in all experimental groups (Fig. 4b, c).
Fig. 4 eNAMPT-monomer immunoneutralisation improves tissue and
systemic inflammation in HFD-fed mice. Serum concentrations of (a)
MCP1, (b) IL-1β and (c) TNF-α in CON- and HFD-fed mice (fed for
10 weeks) injected i.p. with eNAMPT-Ab or non-immune IgG. (d) Gene
expression of proinflammatory genes in isolated islets, (e) insulin and p-
p38 islet immunofluorescence staining of whole pancreatic sections
(magnification ×20), (f) hepatic expression of proinflammatory genes
and (g) white AT proinflammatory gene expression (normalised to control
[CONIgG]). (e, f ) white, CONIgG; light grey, CONAb; black, HFDIgG;
dark grey, HFDAb. †p< 0.05, ††p < 0.01 and †††p < 0.001 for CONIgG vs
HFDIgG; ‡p < 0.05, ‡‡p < 0.01 and ‡‡‡p< 0.001 for HFDIgG vs HFDAb;
and §p< 0.05, §§p< 0.01 and §§§p < 0.001 for CONAb vs HFDIgG
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Furthermore, eNAMPT-Ab reversed HFD-mediated increases
in islet mRNA levels of proinflammatory cytokines (Tnfa,
Il1b, Il6), chemokines (Ccl2, encoding MCP1) and immune
cell markers (Itgam, encoding CD11b; Itgax, encoding
CD11c; Adgre1, encoding F4/80; Fig. 4d). Studies in mono-
cytes have reported that eNAMPT induces proinflammatory
cytokine production in part through activation of p38
mitogen-activated protein kinase (MAPK) [10]. In agreement,
we found that the islet p-p38 immunofluorescence signal
(denoting activated p38) was enhanced in HFD-fed mice com-
pared with CON-fed mice, and that this effect was reversed by
eNAMPT-Ab treatment (Fig. 4e). Chronic inflammation in
liver and white AT is also common in obesity and type 2
diabetes, where it plays a crucial role in disease pathophysiol-
ogy. Consistent with a proinflammatory effect for the
eNAMPT-monomer in these tissues, eNAMPT-Ab lowered
the expression of proinflammatory genes in the liver and AT
of HFD-fed mice (Fig. 4f, g). These data provide strong sup-
port for the notion that eNAMPT immunoneutralisation
improves pancreatic beta cell health and peripheral insulin
resistance through resolution of inflammation in HFD-fed
mice, and that the eNAMPT-monomer is likely to exert pro-
inflammatory effects.
The beneficial effects of eNAMPT-Ab are maintained
3 weeks post-treatment To determine whether the effects of
eNAMPT immunoneutralisation were maintained over time,
eNAMPT-Ab was administered in weeks 9–10, as previously
described. Mice then remained on CON or HFD diets until
week 13 without further eNAMPT-Ab administration. At
3 weeks post-treatment, the eNAMPT-Ab-lowered HFD-
mediated increases in blood glucose enhanced islet insulin
secretion, reduced islet inflammation, and reduced hepatic
triacylglycerol content, hepatic lipogenic gene expression
and hepatic inflammation (Fig. 5). Thus, the beneficial effects
of a single dose regimen of eNAMPT-Ab were maintained for
at least 3 weeks post treatment.
eNAMPT-monomer administration for 14 days induces a
diabetic phenotype in mice Finally, we examined the impact
of experimental elevation of serum eNAMPT-monomer levels
on glycaemic control in mice. Lean, non-diabetic mice were
injected i.p. with recombinant eNAMPT or the equivalent
volume of NaCl (154 mmol/l). eNAMPT administration dou-
bled serum eNAMPT levels to 3.05±0.37 ng/ml (Fig. 6a),
similar to levels in HFD-fed mice. When recombinant
eNAMPT protein was analysed by non-reducing SDS-PAGE
and immunoblotting, a 50 kDa protein band was detected but a
100 kDa protein band was not (ESM Fig. 1f). Moreover,
recombinant eNAMPT treatment did not increase NAD levels
in vitro in MIN6 cells, nor in vivo in mouse white AT (ESM
Fig. 1g, h). These findings suggest that the recombinant
eNAMPT used in this study does not dimerise to promote
NAD biosynthesis, and thus represents monomeric eNAMPT.
Therefore, to mimic elevated dimeric eNAMPT, a separate
group of mice were injected i.p. with NMN, the reaction prod-
uct of the eNAMPT-dimer’s NAD biosynthetic reaction.
The 14-day eNAMPT-monomer administration resulted in
elevated fasting blood glucose levels (Fig. 6b), development
of IGT (0–30 min post-glucose injection; Fig 6c) and whole-
Fig. 5 The beneficial effects of eNAMPT-monomer immunoneutralisation
in HFD-fed mice are maintained for 3 weeks post-treatment. (a) Fed serum
glucose levels, (b) ex vivo GSIS, (c) islet expression of proinflammatory
genes, (d) hepatic triacylglycerol levels, (e) hepatic expression of lipogenic
and gluconeogenic genes and (f) hepatic expression of proinflammatory
genes in CON- and HFD-fed mice (fed for 13 weeks), injected i.p. with
eNAMPT-Ab or non-immune IgG (at weeks 9–10; c, e, f: normalised to
control [CONIgG]). In (b, c, e, f), white, CONIgG; light grey, CONAb; black,
HFDIgG; dark grey, HFDAb. *p< 0.05; **p< 0.01, ***p< 0.001 for all
subparts except (c, e, f) where †p<0.05, ††p<0.01 and †††p<0.001 for
CONIgG vs HFDIgG, ‡p < 0.05, ‡‡p < 0.01, ‡‡‡p < 0.001 for HFDIgG vs
HFDAb and §p<0.05 and §§p<0.01 for CONAb vs HFDIgG
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body insulin resistance, as determined by QUICKI and
HOMA-IR (Fig. 6d, e). These changes were not related to
changes in body weight, serum triacylglycerol or insulin
levels (ESM Fig. 4a–d). Moreover, eNAMPT-monomer
administration led to impaired insulin secretion, as demonstrat-
ed by a lack of islet compensatory response to insulin resistance
(Fig. 6f, g). Consistent with its hypothesised proinflammatory
actions, eNAMPT-monomer administration led to elevated
serum of MCP1 levels (Fig. 6h) and increased liver and white
AT Ccl2 mRNA levels (Fig. 6i), although serum IL-1β and
TNF-α levels and liver andwhite ATmRNA levels of a number
of other proinflammatory markers remained unchanged (ESM
Fig. 4e–h). eNAMPT-monomer administration induced a non-
significant trend towards increased proinflammatory gene
expression in islets (ESM Fig. 4i).
In contrast to the diabetogenic effects of the eNAMPT-
monomer, NMN administration resulted in mild reductions
in blood glucose and serum IL-1β levels, without changes in
body weight, glucose tolerance or insulin sensitivity (ESM
Fig. 5).
Together, these data suggest distinct structure–function
characteristics of eNAMPT monomers and dimers; the
eNAMPT-monomer induced a diabetic phenotype in mice
via NAD-independent proinflammatory effects, whilst
eNAMPT-dimer/NMN elevation led to mild improvements
in glycaemic control.
Discussion
We provide multiple lines of evidence suggesting an important
NAD-independent role for the eNAMPT-monomer in type 2
diabetes: (1) diabetic HFD-fed mice displayed a selective
increase in serum eNAMPT-monomer levels; (2) blocking
eNAMPT action reversed the diabetogenic effects of HFD;
and (3) 14-day administration of the eNAMPT-monomer in-
duced a diabetic phenotype in non-diabetic mice.
Elevated serum eNAMPT levels are reported in type 2
diabetes [2, 3, 20, 22–24], although other studies have
observed decreased or unchanged serum eNAMPT levels in
metabolic diseases [25, 26].
Our findings go some way in clarifying the contradictory
findings regarding eNAMPT and type 2 diabetes by demon-
strating differences in the levels of eNAMPT-monomer and
eNAMPT-dimer in experimental diabetes and highlighting the
relevance of structure–function differences between monomer
and dimer.
The precise function of eNAMPT and the relationship
between raised eNAMPT levels and type 2 diabetes pathophys-
iology remain unresolved. Previous experimental studies have
demonstrated both beneficial and deleterious effects of recom-
binant eNAMPT on insulin secretion and sensitivity in vitro
[27–30]. However, these studies have often examined the acute
effects of eNAMPT, which are unlikely to accurately represent
a diabetic phenotype, or have used supraphysiological concen-
trations of eNAMPT. Crucially, these studies also did not dis-
tinguish between eNAMPT-monomers and eNAMPT-dimers.
Our studies, and those of other groups, have described ben-
eficial acute and chronic effects of NMN, the reaction product
of the eNAMPT-dimer biosynthetic reaction [4, 6, 7, 31, 32].
Consistent with a beneficial effect of the eNAMPT-dimer,
serum and white AT eNAMPT-dimer levels were unchanged
or decreased in HFD-fed mice, whilst 14-day NMN adminis-
tration lowered blood glucose and inflammation in non-
Fig. 6 eNAMPT-monomer
administration for 14 days
induces a diabetic phenotype in
mice. (a) Serum eNAMPT levels,
(b) blood glucose levels,
(c) IPGTT (squares, saline;
triangles, eNAMPT),
(d) QUICKI and (e) HOMA-IR in
mice injected i.p. with
recombinant eNAMPT-monomer
or the equivalent volume of
154 mmol/l NaCl. AUC insulin
response to IPGTTat (f) 0–15min
and (g) 15–60 min, (h) serum
MCP1 levels and (i) Ccl2 gene
expression (white bars, saline;
black bars, eNAMPT). *p< 0.05,
**p< 0.01
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diabetic mice. In contrast, we describe a specific role for the
eNAMPT-monomer in experimental diabetes via functioning
partly through NAD-independent proinflammatory effects.
Proinflammatory effects of eNAMPT in type 2 diabetes have
not previously been reported. However, our findings are broad-
ly in agreement with studies of eNAMPT in other diseases,
although such studies did not distinguish between monomers
and dimers. For example, eNAMPT is reported to induce
monocyte expression and secretion of IL-6, IL-1β and
TNF-α [10], potentially via receptor-mediated mechanisms
[33]. Thus, normalisation of eNAMPT-monomer signalling in
type 2 diabetes would be predicted to resolve inflammation-
mediated beta cell dysfunction and insulin resistance and
improve glycaemic control.
We hypothesise that increased monomer levels are partly
related to AT dysfunction. AT-derived eNAMPT-dimer is
secreted from fully differentiated adipocytes, whilst the mono-
mer may be secreted from poorly-differentiated adipocytes
and immune cells [5, 9, 10, 34–36]. Since poor adipocyte
differentiation and immune cell infiltration are characteristics
of obese AT [37], we hypothesise that such pathophysiologi-
cal changes could explain the increased monomer levels in
HFD-fed mice. In agreement, eNAMPT secretion from the
AT SVF (which contains immune cells and undifferentiated
pre-adipocytes) was markedly increased in HFD-fed mice.
Thus, we hypothesise that obesity-mediated AT dysfunction
results in a phenotypic switch, characterised by elevated
eNAMPT-monomer production from SVF and reduced dimer
secretion from adipocytes. Future studies will elucidate the
precise mechanisms involved in dimer formation and identify
the main cellular source of eNAMPTwithin the SVF.
Together, these studies suggest that the eNAMPT-
monomer is an attractive therapeutic target for type 2 dia-
betes. Future strategies to develop this therapeutic approach
will include development of eNAMPT-monomer receptor
antagonists, specific eNAMPT-monomer inhibitors and
humanised eNAMPT monoclonal antibodies. Humanised
monoclonal antibodies can be engineered with an extended
t½, potentially allowing clinical benefits to be achieved
with only one dose every 1–3 months [38], thus providing
benefits in terms of cost, convenience and compliance.
In summary, we have demonstrated that elevated eNAMPT-
monomer levels contribute to the development of type 2 diabe-
tes. In addition, we have provided proof-of-concept evidence
that selectively blocking the action of eNAMPT-monomer is a
promising therapeutic strategy for the treatment of type 2
diabetes.
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